Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Today’s collaboration with Life Edit is a return to the Danish group’s familiar small, early-stage deal strategy.
The group is fast developing its new atrial fibrillation devices. But will it be fast enough?
Alzheimer’s has already grabbed attention but plenty of big regulatory decisions still loom for Sarepta, Crispr, Astellas and more.
The promise of fast timelines and early revenues lure a new investor into digital medicine.
Improving atrial fibrillation diagnosis is one thing; improving outcomes another.
But difficulties around reimbursement, selling and market value could make it hard for the app maker to live up to its name.
Fianlimab continues to look like biopharma’s leading Lag3 asset, with activity in a new melanoma setting to boot.
Full Dupixent data confirm the drug’s blockbuster potential in the lung disease, but the French drug maker is thinking even bigger.
SRP-9001 heads for its month of regulatory probing, as vaccines from GSK and Pfizer, and Genmab and Abbvie’s bispecific, await FDA approval decisions.
SRP-9001 heads for its month of regulatory probing, as vaccines from GSK and Pfizer, and Genmab and Abbvie’s bispecific, await FDA approval decisions.